Related Experiment Video
Updated: Sep 30, 2025

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
Published on: February 16, 2024
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
C Buske1, M Dreyling2, A Alvarez-Larrán3
1Institute of Experimental Cancer Research, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Insights
The COVID-19 pandemic challenged hematological malignancy (HM) patient care. Experts developed 33 consensus statements to guide optimal clinical decision-making for these patients during the pandemic.
Area of Science:
- Hematology
- Oncology
- Infectious Diseases
- Public Health
Background:
- The COVID-19 pandemic presented significant challenges to the clinical management of patients with hematological malignancies (HMs).
- Optimal care strategies for HMs during the pandemic required urgent clarification.
Purpose of the Study:
- To provide expert advice and clinical guidance on managing patients with hematological malignancies during the COVID-19 pandemic.
- To establish consensus-based statements on critical aspects of HM care amidst the pandemic.
Main Methods:
- An international consortium, led by the European Society for Medical Oncology and the European Hematology Association, was formed.
- Six working packages addressed key clinical questions, followed by a virtual consensus meeting where global experts discussed and voted on statements.
- Statements were revised to achieve consensus on clinical guidance when initial agreement was not reached.
Main Results:
- A consensus was reached on 33 statements.
- These statements provide guidance for clinical decision-making for patients with hematological neoplasms during the COVID-19 pandemic.
Conclusions:
- The developed consensus statements offer crucial guidance for healthcare professionals managing hematological malignancy patients during the COVID-19 pandemic.
- This collaborative effort ensures evidence-based and expert-informed care recommendations.
Background:
The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group.
Methods:
This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance.
Results And Conclusion:
The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
09:43Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
Published on: March 8, 2024
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Treatment Resistant Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Hemodialysis III: Nursing Management
Hematopoiesis